ULK1 and neoplasm: The combination of a Unc-51 Like Autophagy Activating Kinase 1 (ULK1) inhibitor, MRT68921, with an anti-PD-1 monoclonal antibody can increase antigen presentation and therefore restore anti-tumor immunity, by compensating for LKB1 loss, leading to KRAS/LKB1 co-mutant tumor regression [102].